Why Are Hepion Pharma Shares Moving Higher Premarket Monday?
- Hepion Pharmaceuticals Inc (NASDAQ: HEPA) stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial.
- Today, Hepion will share additional data from the Phase 2a AMBITION trial, evaluating CRV431, a potent inhibitor of cyclophilins involved in many disease processes.
- As previously disclosed, the trial achieved all primary endpoints.
- Related Content: Hepion Pharma's NASH Candidate Aces Mid-Stage Study.
- Price Action: HEPA shares are up 16.9% at $1.94 during the premarket session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech News Penny Stocks Health Care Movers Trading Ideas General
